Needham & Company
-
Albireo to Present at Investor Conferences in April
-
Albireo Provides First Quarter 2018 Business Update
-
Albireo to Present at 17th Annual Needham & Company Healthcare Conference
-
Albireo Pharma (ALBO) PT Raised to $50 at Needham & Company; Elobixibat Approval and Royalty Deal
-
Albireo Announces Closing of $74.8 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
-
Albireo Pharma (ALBO) Prices 1.97M Common Stock Offering at $33/Share
-
Albireo Prices $65.0 Million Public Offering of Common Stock
-
Albireo Pharma (ALBO) to Offer Common Stock
-
Albireo Announces Proposed Public Offering of Common Stock
-
Needham & Company Starts Albireo Pharma (ALBO) at Buy
-
Albireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
-
Albireo Pharma (ALBO) Prices 2.2M Common Stock Offering at $20.50/Share
-
Albireo Prices $45.1 Million Public Offering of Common Stock
-
Albireo Pharma (ALBO) Commences Offering of Common Stock
-
Albireo Announces Proposed Public Offering of Common Stock
-
Albireo to Present at Upcoming Investor Conferences

